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Abstract
In the present work, a simple method was used to develop composite curcumin-amine
functionalized mesoporous silica nanoparticles (MSN). The nanoparticles were used to improve
the bioavailability of curcumin in mice through oral administration. We investigated the effect of
particle size on the release profile, solubility and oral bioavailability of curcumin in mice,
including amine functionalized mesoporous silica micron-sized-particles (MSM) and MSN
(100–200 nm). Curcumin loaded within amine functionalized MSN (MSN-A-Cur) had a better
release profile and a higher solubility compared to amine MSM (MSM-A-Cur). The
bioavailability of MSN-A-Cur and MSM-A-Cur was considerably higher than that of ‘free
curcumin’. These results indicate promising features of amine functionalized MSN as a carrier to
deliver low solubility drugs with improved bioavailability via the oral route.
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1. Background
Curcumin is an active agent that can be found from rhizomes
of the Curcuma longa plant. This active agent has a high
potency to treat various diseases (e.g. diabetes, cancer,
allergies, arthritis and Alzheimer’s disease) mainly due to its
anti-oxidant, anti-inflammation and anti-viral properties [1].
Nevertheless, these benefits are hampered by the low bioa-
vailability of curcumin because it has a negligible solubility in
water and only limited solubility in ethanol or acetone [1–3].
The construction of curcumin nanoparticles and nano-for-
mulations is an effective way to increase its bioavailability,
including the use of liposomes, micelles, phospholipid
complexes and curcumin analogs [1]. However, these
organic-based formulations have stability issues. Curcumin
analog has similar properties to its predecessor, but its safety
profile has not been clearly demonstrated and requires further
studies [2].
Over the past decade, mesoporous silica (MS) materials
have been used extensively in many investigations to improve
the efficacy of drug and gene delivery [4–12]. MS materials
have shown promising potential as oral drug or parenteral
drug carriers [13]. Taking the advantages of their very high
surface area and pore volume, MS materials are capable of
carrying a large quantity of cargos for various applications,
including catalysis, chemical synthesis, enzyme immobiliza-
tion and drug delivery. Previous research showed the use of
MS to increase the solubility of various insoluble drugs such
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as doxorubicin and paclitaxel [10, 14]. Different strategies
have also been reported to produce curcumin-mesoporous
silica nanocomposites, including the formation of guanidine
functionalized PEGylated mesoporous silica nanoparticles
(MSN) [15], lipid bilayer-coated curcumin-based MSN [16],
curcumin-loaded silica encapsulated porous chitosan [17],
mesoporous silica coated curcumin-lipid core [18], curcumin-
silica composites with double functionalization [19] and
composite hydrogels of chitosan-MSN [20].
These drug delivery systems are generated from complex
synthesis and functionalization processes, limiting their
practical applications due to the time consuming, rigorous
procedures and high cost of production. A simple method that
can produce multifunction carriers for effective drug delivery
is in needed.
Studies have shown that the physicochemical properties
of MS, including pore size, particle size, pore structure and
surface functionalization affect the release profile of loaded
molecules, which in turn influence the solubility [10, 19, 21–
23]. Careful optimization of these parameters can be a facile
way to improve the bioavailability of various low solubility
drugs. Previous reports on drug molecule-silica nanocompo-
sites mostly focused on either mesoporous silica micron-
sized-particles (MSM) or MSN with small pore size (<3 nm)
[10, 19, 21–23]. Small pores induce stronger steric hindrance
to the adsorbed molecules compared to large pores. Further
increasing the drug loading causes ‘congestion’ and limits the
molecule diffusion in the nanopores, causing pore blocking,
low loading and incomplete release of cargo mole-
cules [10, 23].
To overcome the limitations, here we report amine
functionalized cubic mesostructured MSN with 3D inter-
connected large pore size (10 nm) as carriers to improve
curcumin bioavailabiliy in vivo. Comparing with the 2D pore
system, the 3D pore system has a better mass transfer and
more resistance to pore blockage [24]. Surface functionality is
another important parameter of drug carriers [25–27] and
amine functionalization onto silica materials has been proved
to be an effective strategy in creating a controlled release
profile for various molecules [28, 29]. In addition, Mitra et al
showed that the interaction between primary amine of chit-
osan and phenolic group of curcumin via hydrogen bonding
improved curcumin binding and stability [30]. The effect of
particle size on curcumin release, solubility and bioavail-
ability is also investigated. To the best of our knowledge, this
is the first report using large-pore cubic mesostructured MSN
for improving in vivo curcumin bioavailability through oral
administration.
2. Materials and methods
2.1. Chemicals
Triblock poly(ethylene oxide)-b-poly(propylene oxide)-b-
poly(ethylene oxide) copolymer EO106PO70EO106 (Pluronic
F127, MW=12 600), tetraethoxysilane (TEOS, 99%), 1,3,5-
trimethylbenzene (TMB), 3-aminopropyltriethoxysilane
(APTES, 99%), potassium chloride (KCl), phosphate buffer
tablets and Tween 80 were purchased from Aldrich. A
fluorocarbon surfactant (FC-4) was purchased from Yick-Vic
Chemicals & Pharmaceuticals (HK) Ltd. All chemicals were
used as received without purification.
2.2. Synthesis of MSM and MSN with a cubic mesostructure
MSM with a cubic mesostructure were synthesized following
the previous method by Fan et al with some modifications
[31]. Typically, 1 g of F127 and 5 g of KCl were mixed in
60 ml of 2M HCl at 20 °C (synthesis temperature) and stirred
for 30 min. Then, 1.6 g of TMB was added and stirring was
continued for 6 h. 4 g of TEOS was added under stirring, and
the mixture was continuously stirred for 24 h at 20 °C. Then,
the mixture solutions were transferred to an autoclave and
heated at 130 °C for 24 h. After hydrothermal treatment, the
product was separated, washed and dried. The surfactant was
removed by calcination at 550 °C for 6 h.
MSN with nano-sizes and a cubic mesostructure were
synthesized following the previous method by Ying et al with
some modification [32]. 0.5 g of F127 and 1.4 of FC4 were
mixed in the solutions of 60 ml of 0.02M HCl then 0.5 g of
TMB was added. After the solution was stirred for 4 h, TEOS
was added into the solutions and was stirred for 24 h at 20 °C.
The solutions were then moved to an autoclave and heated at
130 °C for 24 h of hydrothermal treatment. The product was
separated, washed and dried. The surfactant was removed by
calcination similar to MSM synthesis.
2.3. APTES modification
Amine functionalization was conducted via a grafting
method. 0.6 g of mesoporous silica (MSM, MSN) was added
into 30 ml of toluene. The mixture was stirred and heated to
70 °C. 1.2 ml of APTES was added into the mixture and the
stirring was continued for 20 h. The product was centrifuged
and dried [27]. The products were denoted MSM-A and
MSN-A.
2.4. Curcumin loading, in vitro release and solubility test
The curcumin loading, release and solubility test were per-
formed based on a method reported by Jambhrunkar et al [8].
200 mg of MS (MSM-A, MSN-A) was mixed with 50 mg of
curcumin in a rotary evaporation flask. 20 ml of ethanol was
added and the mixture was sonicated for 2 min using a bath
sonicator. Ethanol was evaporated slowly under vacuum at a
temperature of 55 °C. Finally curcumin loaded MS was
obtained (MSM-A-Cur, MSN-A-Cur). A dialysis bag method
was used to determine in vitro release of MSM-A-Cur and
MSN-A-Cur. 25 mg of curcumin loaded silica particles were
mixed with 5 ml of release solution (phosphate buffered saline
(PBS) buffer+0.8% Tween 80). The mixture was added into
the dialysis bag (Sigma Aldrich) with 14 kDa molecular
weight cutoff. The curcumin-silica loaded mix was immersed
in 200 ml release solution. Then 1.0 ml of samples were
collected at a certain interval time to be determined by con-
centration. The samples were analyzed using a UV–vis
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spectrophotometer at 432 nm. For the solubility test, an
excess of curcumin loaded MS was added into 2 ml of water.
The mixture was kept under stirring for 48 h at 37 °C. A
supernatant was collected and checked with a UV–vis spec-
trophotometer at 432 nm.
2.5. Bioavailability test
Bioavailability of free curcumin, MSM-A-Cur and MSN-A-
Cur in mice was compared. Twenty-four male rats weighing
250±20 g were randomly divided into three treatment
groups and given free curcumin, MSM-A-Cur and MSN-A-
Cur suspensions. The rats were fasted for 24 h before the
experiment. A dose of each formulation (50 mg kg−1, con-
tains 10 mg curcumin/kg) was given through oral adminis-
tration. Subsequently, 300 μl of blood sample was collected
from the tail into EDTA tubes at indicated time intervals.
Plasma samples were separated by centrifugation at 3000 rpm
for 15 min. Curcumin pharmacokinetic parameters were
determined by using high performance liquid chromato-
graphy. The mobile phase consisted of acetic acid 2%: acet-
onitrile in a combination of 60:40. The mobile was pumped at
a flow rate of 1 ml min−1 at room temperature. After injection
of the sample into the HPLC, the UV detection wavelength
was set at 428 nm.
2.6. Characterization
Transmission electron microscopy (TEM) images were
obtained by a JEOL 1010 electron microscope with an
acceleration voltage 100 kV. Nitrogen sorption isotherms of
the samples were obtained using a Quantachrome’s Quad-
rasorb SI analyser at 77 K. Before the measurements, the
samples were degassed overnight at 110 °C in vacuum. The
Brumauer–Emmett–Teller (BET) surface area was calculated
using experimental points at a relative pressure (P/P0) of
0.05–0.25. The total pore volume was calculated from the N2
amount adsorbed at the highest P/P0 (P/P0=0.99). For
cubic structures, the cavity pore size and entrance pore size
are determined from the adsorption and desorption branches,
respectively, by using Barrett–Joyner–Halenda (BJH) model.
TGA/DSC 1 (Mettler-Toledo AG) was used for thermo-
gravimetric analysis (TGA) at a heating rate of 2 °Cmin−1
under a nitrogen flow of 20 ml min−1. XRD patterns were
collected on a German Bruker D8 Advanced x-ray Dif-
fractometer with Ni filtered Cu Kα radiation (40 kV, 30 mA).
Each sample was scanned with attenuated total reflectance
Fourier transform infrared spectroscopy (ATR-FTIR). A total
of 128 scans were conducted within 350–4000 cm−1.
3. Results and discussion
3.1. Synthesis and characterization
Mesoporous silica materials with a cubic mesostructure and
two different particle sizes were synthesized. The TEM
images (figure 1) indicate the ordered structures of MSM (A)
and MSN (B). The MSN had a particle size around 100 nm,
while MSM showed micron-size particles with significantly
larger size (around 1 μm). The typical interconnected pores
can be seen from figure 1(A) [31].
The XRD patterns (figure 2) of MSM and MSN show
similar peaks that can be indexed as 111, 220 and 311
reflections associated with a cubic symmetry Fm m3( ¯ ) [31].
Nitrogen sorption isotherms of MSM and MSN are presented
in figure 3 showing a type-2 hysteresis, which is typical of
cubic mesostructures with large pores connected by entrances
with smaller sizes. The pore size of both MSM and MSN
were calculated to be 10 nm.
Functionalization of porous silica materials was con-
ducted by using a grafting method [27]. A total weight loss of
18% was observed after APTES functionalization of MSN
based on TGA (figure 4), which is attributed to the grafting of
amine moiety grafted on the surface of MSN. Successful
amine functionalization is confirmed further from FTIR ana-
lysis (figure 5). The FTIR spectra of MSN, MSN-A and
MSN-A-Cur showed similar peaks at 950 cm−1 (Si-OH) and
1100 cm−1 (Si-O-Si). The amine functionalized MSN (MSN-
A) exhibited a broad peak at around 2800 to 3300 cm−1
indexed to N–H bending and stretching of primary amines
and another peak at 1550 cm attributed to N–H bending
vibration [33].
The FTIR spectra of MSN-A-Cur had several peaks
similar to free curcumin (Δ). These peaks were found at
3020 cm−1 (C–H stretching of aromatic rings), 1650 cm−1
(C=O stretching), 1510 cm−1 (C=O and C=C vibration) and
Figure 1. TEM images of (A) MSM and (B) MSN.
Figure 2. Powder XRD patterns of MSM and MSN.
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1300 cm−1 (CH3 bending) [8]. The spectra of MSN-A-Cur
showed a new peak at 3100 cm−1 (*), suggesting the forma-
tion of hydrogen bonding between amine groups of MSN-A
and phenolic hydroxyl group of curcumin [30].
3.2. In vitro release and solubility of curcumin
Figure 6 shows the in vitro release profiles for free curcumin,
MSM-A-Cur and MSN-A-Cur. The drug release in the free
curcumin group reached a plateau at ∼5 h with an accumu-
lated release amount of just 4%. The amount of curcumin
released to the media was higher in both MSM-A and MSN-A
groups. Moreover, both silica groups showed a prolonged
release profile with the release reaching a plateau after 48 h.
The curcumin released from MSN-A reached 12%, higher
than that in MSM-A group (9%). The results clearly show that
the use of amine functionalization MSN successfully reg-
ulates the curcumin release and creates a prolonged release.
The release amounts of MSN-A and MSM-A were higher
compared to previously reported MS materials. It was
reported that the curcumin release amount from amine func-
tionalized MSU-2 with a pore size of 4.7 nm and amine
functionalized MCM-41 with a pore size of 1.8 nm reached
only 8.8% and 1.5%, respectively [19]. It can be seen that
pore size has influence on the release content of curcumin.
Large pores and small particle sizes lead to a higher release
amount of curcumin.
The solubility of curcumin in the three groups ( free
curcumin, MSM-A-Cur and MSN-A-Cur) is presented in
figure 7 for a direct comparison. The solubility of curcumin in
the MSN-A group was almost ten times higher than the free
curcumin group and almost twice as high than the MSM-A
group. The significant increase of curcumin solubility of
MSN-A and MSM-A compared to free curcumin should be
attributed to the decrease of curcumin particle size. It is
generally known that reducing drug particle size enhances
drug solubility [8, 34]. The particle sizes of curcumin
encapsulated within nanopores of MSM- A and MSN-A were
notably reduced compared to the free curcumin.
In addition, the MS particle size has influence on the
effectiveness of mass diffusion. The nano-size particles
(MSN-A) have similar structures to the micron-size particles
(MSM-A). The reduced diffusion length alleviates the steric
hindrance and accelerates particle release, which causes
higher dissolution rate and finally increased curcumin solu-
bility [13].
The in vivo bioavailability of free curcumin, MSN-A-Cur
and MSM-A-Cur in mice was compared through oral deliv-
ery. Three groups of mice were given curcumin, MSN-A-Cur
and MSM-A-Cur with the same curcumin dosage of
50 mg kg−1. Blood samples were collected to detect the cur-
cumin content. During the analysis, the curcumin concentra-
tion in the free curcumin group was low at all time points
(figure 8). In contrast, the curcumin concentration in the
Figure 3. Nitrogen sorption and pore distribution of MSM and MSN.
Figure 4. TGA profile of MSN and MSN-A.
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MSN-A group had the highest solubility at all time points
compared to the MSM-A-Cur and free curcumin groups
(figure 8). Pharmacokinetic profiles of MSN-A and MSM-A
in the bioavailability test after oral delivery can be seen in
table 1. MSN-A had a higher maximum curcumin con-
centration (Cmax) of 0.0291 μg ml
−1 in plasma compared to
MSM-A (0.0105 μg ml−1). Both samples had similar
tmax=3 h (tmax is the time at which the maximum con-
centration is observed). The value of calculated area under the
concentration-time curve in the time period of 0–6 h (AUC0-6)
for MSN is 3.6 times higher than that of MSM-A. Due to the
very low reading of curcumin concentration in the free cur-
cumin group, its AUC0-6 value was not calculated.
Figure 5. FTIR analysis of various samples.
Figure 6. In vitro release profile of MSN-A-Cur, MSM-A-Cur and
free curcumin.
Figure 7. Aqueous solubility of MSN-A-Cur, MSM-A-Cur and free
curcumin.
Figure 8. Bioavailability test of MSN-A-Cur, MSM-A-Cur and free
curcumin.

















t1/2 (h) 719,28±479,73 785,71±504,39
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In summary, MSN-A-Cur showed a better release profile,
solubility and bioavailabity compared to MSM-A-Cur and
free curcumin due to the following distinct benefits: a cubic
mesostructure and 3D interconnected pores, a large pore size
and reduced diffusion length. These properties together with
amine functionalization support a maximum release of cur-
cumin in a sustained manner. The fast release profile of
curcumin from MSN-A improved the curcumin dissolution
rate and finally increased curcumin bioavailabilty [13].
4. Conclusions
A curcumin-amine mesoporous silica nanoparticle composite
has been prepared using a simple approach. This approach
improved the in vitro solubility of curcumin and, more
importantly, the in vivo bioavailability. Our strategy using
amesoporous silica nanoparticle with 3D interconnected
large pores as nanocarriers is promising for the development
of curcumin oral delivery formulations for future clinical
applications.
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